Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 66, Issue 7, 2006, Pages 976-982

  Suchowersky, O ^a   Gronseth, G ^b   Perlmutter, J ^c   Reich, S ^d   Zesiewicz, T ^e   Weiner, W J ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF KANSAS   (United States)

^c Division of General Medical Sciences   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^e Movement Disorder Center   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FOOD ADDITIVE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; UBIDECARENONE;

ALTERNATIVE MEDICINE; ARTICLE; CLINICAL TRIAL; DATA BASE; DISEASE COURSE; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; MOTOR PERFORMANCE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; SPEECH THERAPY; VITAMIN SUPPLEMENTATION; FALLING; HEALTH CARE QUALITY; NEUROLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; STANDARD; UNITED STATES;

ACCIDENTAL FALLS; COMPLEMENTARY THERAPIES; HUMANS; LEVODOPA; NEUROLOGY; PARKINSON DISEASE; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 33646104205     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000206363.57955.1b     Document Type: Article

References (60)

1. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
2. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology 2001;57:790-794.
3. Carter J, Borenstein A, Schwartz S, Zesiewicz T. Nutraceutical use in Parkinson's disease patients. Mov Disord 2003;18:1089.
4. Wright JC. Nonpharmacologic management strategies. Med Clin North Am 1999;83:499-508, viii.
5. Biglan KM, Holloway RG. Surrogate endpoints in Parkinson's disease research. Curr Neurol Neurosci Rep 2003;3:314-320.
6. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
7. Clarke C, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002;360:1767-1769.
8. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32 Suppl:S128-132.
9. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-183.
10. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8:271-276.
11. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
12. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
13. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-1938.
14. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
15. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002;109:1433-1443.
16. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
17. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
18. Tasker RR, DeCarvalho GC, Li CS, Kestle JR. Does thalamotomy alter the course of Parkinson's disease? Adv Neurol 1996;69:563-583.
19. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-1556.
20. Ferry P, Johnson M, Wallis P. Use of complementary therapies and non-prescribed medication in patients with Parkinson's disease. Postgrad Med J 2002;78:612-614.
21. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004;75:1672-1677.
22. Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 2000;176: 124-127.
23. Vaidya AB, Rajagopalan TG, Mankodi NA, et al. Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak. Neurol India 1978;26:171-176.
24. HP-200 Parkinson's Disease Study Group. An alternative medicine treatment for Parkinson's disease: results of a multicenter trial. J Altern Complement Med 1995;1:249-255.
25. Apaydin H, Ertan S, Ozekmekci S. Broad bean (Vicia faba) - a natural source of L-dopa-prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations. Mov Disord 2000;15:164-166.
26. Rabey JM, Vered Y, Shabtai H, Graff E, Harsat A, Korczyn AD. Broad bean (Vicia faba) consumption and Parkinson's disease. Adv Neurol 1993;60:681-684.
27. Rabey JM, Vered Y, Shabtai H, Graff E, Korczyn AD. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 1992;55:725-727.
28. Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv Neurol 1983;37:51-60.
29. McGeer PL, Zeldowicz L, McGeer EG. A clinical trial of folic acid in Parkinson's disease. Can Med Assoc J 1972;106:145-146 passim.
30. Schwarz J, Trenkwalder C, Gasser T, Arnold G, Oertel WH. Folinic acid therapy fails to improve early Parkinson's disease: a two week placebo controlled clinical trial. J Neural Transm Park Dis Dement Sect 1992; 4:35-41.
31. Rabinstein AA, Shulman LM. Acupuncture in clinical neurology. The Neurologist 2003;9:137-148.
32. Zhuang X, Wang L. Acupuncture treatment of Parkinson's disease: a report of 29 cases. J Trad Chinese Med 2000;20:265-267.
33. Walton-Hadlock J. Primary Parkinson's disease: The use of tuina and acupuncture in accord with an evolving hypothesis of its cause from the perspective of Chinese traditional medicine: part 2. Am J Acupuncture 1999;27:31-49.
34. Chen L. Clinical observations on forty cases of paralysis agitans treated by acupuncture. J Trad Chinese Med 1998;18:23-26.
35. Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 2002;17:799-802.
36. Elster E. Upper cervical chiropractic management of a patient with Parkinson's disease: a case report. J Manipulative Physiol Ther 2000; 23:573-577.
37. Wells MR, Giantinoto S, D'Agate D, et al. Standard osteopathic manipulative treatment acutely improves gait performance in patients with Parkinson's disease. J Am Osteopath Assoc 1999;99:92-98.
38. Duval C, Lafontaine D, Hebert J, Leroux A, Panisset M, Boucher JP. The effect of Trager therapy on the level of evoked stretch responses in patients with Parkinson's disease and rigidity. J Manipulative Physiol Ther 2002;25:455-464.
39. Shumaker RG. The response of manual motor functioning in Parkinsonians to frontal EMG biofeedback and progressive relaxation. Biofeedback Self Regul 1980;5:229-234.
40. Stallibrass C, Hampson M. The Alexander technique: its application in midwifery and the results of preliminary research into Parkinson's. Complementary Ther Nursing Midwifery 2001;7:13-18.
41. Stallibrass C. An evaluation of the Alexander technique for the management of disability in Parkinson's disease: a preliminary study. Clin Rehabil 1997;11:8-12.
42. Stallibrass C, Sissons P, Chalmers C. Randomized controlled trial of the Alexander technique for Parkinson's disease. Clin Rehabil 2002;16: 695-708.
43. Bohannon R. Physical rehabilitation in neurology. Curr Opin Neurol 1993;6:765-772.
44. de Goede C, Keus S, Kwakkel G, Wagenaar R. The effect of physical therapy in Parkinson's disease: a research synthesis. Arch Phys Med Rehabil 2001;82:509-515.
45. Deane KH, Jones D, Playford ED, Ben-Shlomo Y, Clarke CE. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001:CD002817.
46. Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2003;74:158-162.
47. Marchese R, Diverio M, Zucchi F, Lentino C, Abbruzzese G. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 2000;15:879-883.
48. Miyai I, Fujimoto Y, Ueda Y, et al. . Treadmill training with body weight support: its effect on Parkinson's disease. Arch Phys Med Rehabil 2000;81:849-852.
49. Miyai I, Fujimoto Y, Yamamoto H, et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2002;83:1370-1373.
50. Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003;84:1109-1117.
51. Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E, Nappi G. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psychosom Med 2000;62:386-393.
52. Chandler C, Plant R. Parkinson's disease: studies in psychological and social care. A targeted physiotherapy service for people with Parkinson's disease from diagnosis to end stage: a pilot study. BPS Books 1999;256-279R.
53. Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology 1994;44: 376-378.
54. Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. Cochrane Database Syst Rev 2001:CD002814.
55. Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy for dysarthria in Parkinson's disease. Cochrane Database Syst Rev 2001:CD002812.
56. Scott S, Caird FI. Speech therapy for Parkinson's disease. J Neurol Neurosurg Psychiatry 1983;46:140-144.
57. Ramig LO, Countryman S, O'Brien C, Hoehn M, Thompson L. Intensive speech treatment for patients with Parkinson's disease: short- and long-term comparison of two techniques. Neurology 1996;47: 1496-1504.
58. Robertson SJ, Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy and long term effects of intensive treatment. Br J Disord Commun 1984;19:213-224.
59. Johnson JA, Pring TR. Speech therapy and Parkinson's disease: a review and further data. Br J Disord Commun 1990;25:183-194.
60. Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001;16:79-83.